Mini-review of the presentation held at the yearly Symposium of the German Evolutionary Medicine
Zsófia Clemens, Csaba Tóth
International Center for Medical Nutritional Intervention (ICMNI) – Paleomedicina Hungary
In the presentation, we give an overview of our clinical experience and research with the paleolithic ketogenic diet (PKD), a diet that was developed by the ICMNI team. Since 2012 we have been exclusively using this approach in the treatment of a wide array of chronic conditions. We use the combined term ”paleolithic ketogenic” because the diet has its roots in both, the paleolithic and the ketogenic diet. The PKD combines the benefits of the two diets while excluding shortcomings of both diets. We have to emphasize the fact that both, the classic version of the ketogenic diet and the popular version of the paleolithic diet are associated with side-effects. The side-effects of the classic ketogenic diet have been well-documented through its use over the last hundred years, whereas, the shortcomings of the popular paleolithic diet are less well-known. As examples for the side-effects, we present a patient who after 7 years on the popular paleolithic diet, developed severe atherosclerosis, and another patient who, after following the classic ketogenic diet for 17 years, developed tophies in multiple locations on hands and feet. Since 2012 we have been using the PKD on more than 4000 patients including those with autoimmune diseases, cancer, psychiatric and neurologic conditions. In the presentation, we focus on presenting data on type 1 diabetes (T1DM) and cancer patients, as well as showing research data related to intestinal permeability measurements in healthy persons as well as in patients.
Type 1 diabetes mellitus (T1DM)
Three major benefits are known to be associated with low carb (or ketogenic) diets: (1) glucose control, (2) decreasing insulin need and (3) decreasing the number of hypoglycemic episodes. The PKD confers the same benefits in T1DM but in addition, it also ensures inflammation control which is of utmost importance given the autoimmune origin of the disease. By controlling inflammation, the PKD, likely prevents the development of long-term complications. Moreover, in patients with new-onset T1DM, intervening with the PKD also results in preventing further decay of their own insulin production as shown by stable or even increased C-peptide measurements following a shift toward the PKD. In the presentation, we show six cases with T1DM where normoglycemia and long-term insulin freedom was achieved, along with preserved C-peptide production. We emphasize that measuring C-peptide in any low-carb diet may be misleading as regards as the assessment of the own insulin production capacity. In order to differentiate the effect of a low-carb diet and the compromised insulin capacity itself, as a new tool, we have introduced the measurement of the stimulated C-peptide in addition to the regular fasting C-peptide.
C-peptide in a T1DM patient following the PKD for three years. Note that C-peptide was preserved during follow-up. C-peptide after stimulation was in the normal range.
We present our cancer-PKD database including 47 patients. An assessment of the database shows that out of all patients, long-term survivors are those who highly adhere to the PKD, and along with this, denied chemotherapy and radiotherapy. We highligt the case of a histologically-proven glioblastoma patient who has been on the PKD as a stand-alone therapy, and is still progression-free and symptom-free at 25 months on the PKD and 32 months after diagnosis onset. Another glioblastoma patient who also highly adhered to the PKD but in addition used radiotherapy as well as alternative treatments including HBOT and supplements died at 11 months on the diet.
Cancer patients who outperformed their diagnosis not just by being alive but also by being progression-free. A temporary decrease in the PKD adherence in a patient with recurrent brain tumor, was associated with slight progression, while going back to strictly following the diet was associated with regression. Note that none of the patients used radiotherapy and chemotherapy along with the diet therapy and only one patient had radiochemotherapy before starting the diet therapy.
Intestinal permeability (IP) measurements
We use the PEG400 challenge test to measure IP. The PEG400 has many benefits over other IP tests. Since 2017 we have been measuring IP in our own laboratory in collaboration with the Department of Applied Biotechnology and Food Science, University of Technology and Economy, Budapest. Measurements show that following the PKD is associated with normal IP, and that originally elevated IP (associated either with the Western-type diet, the classic ketogenic diet or the paleolithic diet) normalizes after a shift toward the PKD in both healthy persons and patients. Taking medicines, supplements can also be associated with elevated IP.
PEG400 test result in a patient with Hodgkin lymphoma. The patient was originally following the classic ketogenic diet with multiple supplements. The first measurement was done right before PKD onset (and after several cycles of chemotherapy regimens). The second measurement was done at 3.5 months on the PKD without chemotherapy. Normalization of the intestinal permeability was paralleled by symptomatic improvement.